P&U Colestid OTC development investment of over $6 mil. includes consumer use study.
This article was originally published in The Tan Sheet
Executive Summary
COLESTID OTC DEVELOPMENT INVESTMENT OF OVER $6 MIL. since 1989 includes expenditures on a consumer use study in several major urban markets, according to Pharmacia & Upjohn. The company initiated the study in January and expects to complete the project at the end of 1997. Information regarding the company's program to switch its prescription cholesterol-reducing drug Colestid (colestipol) to OTC status was disclosed by Pharmacia & Upjohn in a trademark infringement lawsuit filed against Pharmanex last spring in Grand Rapids, Mich. federal court.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning